Viking Holdings Ltd continues to outperform, driven by strong baby boomer demand, double-digit revenue growth. Learn more ...

The GLP-1 drug market has surged dramatically in the past four years, driven by soaring demand for weight-loss treatments ...

All this means that Viking is a great biotech buy -- its candidate is promising, you can benefit from getting in on the dip, and momentum has been picking up. But you don't have to rush to scoop up ...

Major U.S. indices closed mixed on Tuesday, with the Dow Jones Industrial Average climbing 1.2% to 47,927.96 and the S&P 500 ...

The weight loss drug company was counted out far too early in the summer, but investors are warming to it again.

Viking Holdings (NYSE:VIK) just named nine new river ships at a ceremony in Basel, Switzerland. This marks its 100th vessel and solidifies its lead as the cruise line with the largest fleet. See our ...

With significant upside potential and hedge fund interest, Viking Therapeutics, Inc. (NASDAQ:VKTX) secured a spot on our list ...

After a thorough review of the options trading surrounding Viking Therapeutics, we move to examine the company in more detail. This includes an assessment of its current market status and performance.

The article " Viking Therapeutics: High Risk, High Reward Play " first appeared on MarketBeat.

VENTURE Study Exploratory Analysis Shows VK2735 Improved Cardiometabolic Parameters After 13 Weeks; Reducing Prediabetes and Metabolic Syndrome SAN DIEGO, Nov. 6, 2025 /PRNewswire/ -- Viking ...

Management reassured investors that there could be substantial value in its lead drug candidate, VK2735.

Industrial Fire Sprinklers Market Surges to USD 7.2 Billion by 2033, Propelled by 6.5% CAGR - Verified Market Reports (R) ...